Cosmetic composition comprising chlorogenic acid and taurine

Abstract

The present invention relates to a cosmetic composition comprising chlorogenic acid and taurine as active ingredients. Specifically, the present invention relates to a cosmetic composition having excellent effects such as skin wound recovery, skin elasticity enhancement, skin wrinkle alleviation, skin moisturization, skin radiance improvement, or anti-inflammation. In addition, the present invention relates to: a functional food composition and a quasi-drug composition, which comprise chlorogenic acid and taurine as active ingredients; and uses thereof.

Description

Cosmetic composition containing chlorogenic acid and taurine

[0001] The present invention relates to a cosmetic composition comprising chlorogenic acid and taurine as active ingredients, and more particularly, to a cosmetic composition having excellent effects such as skin wound healing, skin elasticity enhancement, skin wrinkle improvement, skin moisturizing, skin radiance improvement, and anti-inflammation. In addition, the present invention relates to a functional food composition, a quasi-drug composition, and uses thereof comprising chlorogenic acid and taurine as active ingredients.

[0002]

[0003] External factors such as fungal infections, UV stimulation, or fine dust, and internal factors such as stress and the body's immune response cause inflammation and oxidative stress in skin tissue, leading to complex problems such as wrinkle formation, weakened skin elasticity, decreased skin moisture, and additional micro-wounds.

[0004] Once a wound occurs on the skin, immune cells in the body flock to the wound site to prevent further infection and wound deterioration, secreting pro-inflammatory and anti-inflammatory cytokines. If this process is disrupted by the regulation of pro-inflammatory cytokines, chronic inflammation can occur, leading to additional problems such as wrinkles, worsening elasticity, and decreased hydration.

[0005] Staphylococcus aureus, Pseudomonas aeruginosa, and Cutibacterium acnes (C. acnes), which are common on the skin, have been identified as causative agents of skin inflammation. In particular, C. acnes, which accounts for the largest proportion, is the main culprit in inducing a hyperinflammatory response, and the proinflammatory cytokines additionally secreted by C. acnes not only delay wound healing but also cause chronic inflammation, post-inflammatory hyperpigmentation (PIH), and inhibition of collagen synthesis.

[0006] Accordingly, consumer needs are increasing for the development of cosmetic materials that can provide a combination of skin wound healing, skin elasticity and wrinkle improvement, moisturizing improvement, and soothing effects (10-2024-0083156 A).

[0007]

[0008] In the present invention, it was confirmed that the combination of chlorogenic acid and taurine was superior in its effects on skin wound recovery, skin elasticity enhancement, skin wrinkle improvement, skin radiance improvement, skin moisturizing, and anti-inflammation compared to either alone, and it was confirmed that there were no problems with the formulation stability.

[0009]

[0010] One object of the present invention is to provide a cosmetic composition comprising chlorogenic acid and taurine as active ingredients.

[0011] Another object of the present invention is to provide a functional food composition comprising chlorogenic acid and taurine as active ingredients.

[0012] Another object of the present invention is to provide a pharmaceutical composition comprising chlorogenic acid and taurine as active ingredients.

[0013] Another object of the present invention is to provide a method for improving skin, comprising a step of applying or administering to a subject a composition comprising chlorogenic acid and taurine as active ingredients.

[0014] Another object of the present invention is to provide a composition containing chlorogenic acid and taurine as active ingredients for improving skin.

[0015]

[0016] The cosmetic composition comprising chlorogenic acid and taurine of the present invention as active ingredients has excellent effects in skin wound recovery, skin elasticity enhancement, skin wrinkle improvement, skin moisturizing, skin radiance improvement, and / or anti-inflammatory effects.

[0017]

[0018] Figure 1 shows the discoloration of the formulation according to the content of chlorogenic acid of the present invention.

[0019] Figure 2 shows the wound healing ability according to the weight ratio of chlorogenic acid and taurine of the present invention.

[0020] Figure 3 shows the synergistic effect of chlorogenic acid and taurine of the present invention on promoting wound healing.

[0021] Figure 4 shows the barrier strengthening synergy effect of chlorogenic acid and taurine of the present invention.

[0022] Figure 5 shows the change in skin radiance and improvement rate of chlorogenic acid and taurine of the present invention.

[0023]

[0024] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in the present invention can also be applied to each other description and embodiment. In other words, all combinations of the various elements disclosed in the present invention fall within the scope of the present invention. Furthermore, the scope of the present invention should not be considered limited by the specific descriptions described below.

[0025] Furthermore, those skilled in the art will recognize or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments of the invention described herein. Furthermore, such equivalents are intended to be encompassed by the present invention.

[0026] To achieve the above object, one aspect of the present invention provides a cosmetic composition comprising chlorogenic acid and taurine as active ingredients.

[0027] The term 'chlorogenic acid' of the present invention is a type of polyphenol compound, has a chemical formula of C16H18O9, and can be represented by the following chemical formula 1.

[0028] [Chemical Formula 1]

[0029]

[0030] The chlorogenic acid of the present invention can be purchased commercially or synthesized using a method known in the art.

[0031] The chlorogenic acid of the present invention may be contained in an amount of about 0.0001 to 3 wt% based on the total weight of the composition, but is not limited thereto. For example, the chlorogenic acid of the present invention is present in an amount of about 0.0001 to 3 wt%, about 0.0005 to 2 wt%, about 0.001 to 2 wt%, about 0.01 to 2 wt%, about 0.0001 to 1 wt%, about 0.0005 to 1 wt%, about 0.001 to 1 wt%, about 0.01 to 1 wt%, about 0.0001 to 0.5 wt%, about 0.0005 to 0.5 wt%, about 0.001 to 0.5 wt%, about 0.01 to 0.5 wt%, about 0.0001 to 0.005 wt%, about 0.0005 to 0.005 wt%, about 0.001 to 0.5 wt%, about 0.0001 to 0.005 wt%, about 0.0005 to 0.005 wt%, about 0.001 to It can be 0.005 wt%, about 0.0001 to 0.003 wt%, about 0.0005 to 0.003 wt%, about 0.001 to 0.003 wt%, about 0.0001 to 0.002 wt%, about 0.0005 to 0.002 wt%, about 0.001 to 0.002 wt%, about 0.0001 to 0.001 wt%, or about 0.0005 to 0.001 wt%.

[0032] In this invention, to discover a material with a multi-effect profile, the pro-inflammatory cytokine suppression effects of polyphenol compounds were first investigated. Chlorogenic acid, while possessing excellent antioxidant / anti-inflammatory properties, has limitations, such as discoloration and poor formulation stability when applied to cosmetic formulations at concentrations exceeding a certain level. Furthermore, cytotoxicity to keratinocytes was confirmed at concentrations exceeding a certain level.

[0033] Although it is effective, there is a possibility that formulation stability and safety issues may arise when prescribed in amounts exceeding a certain level. Therefore, we sought to find a material that could create a synergistic effect for skin improvement through a combination with chlorogenic acid, which cannot be used in concentrations above a certain level.

[0034]

[0035] The term 'Taurine (2-aminoethane sulfur acid)' of the present invention is a type of beta amino acid, an antioxidant with anti-inflammatory effects, and is known to increase membrane stability and prevent calcium accumulation. Although taurine has low cell membrane permeability due to its structurally high hydrophilicity (sulfonic acid), it efficiently passes through lipophilic membranes through the sodium / chloride-dependent taurine transporter (TauT), so taurine plays a very important role in maintaining skin homeostasis. Since the taurine content in the skin gradually decreases due to aging, taurine supplementation is necessary to maintain skin homeostasis and regenerative capacity. Therefore, the present invention sought to use taurine as a candidate substance for enhancing skin wound healing capacity. The taurine can be purchased commercially or synthesized by a method known in the art.

[0036] The taurine of the present invention may be contained in an amount of about 0.0001 to 5 wt% based on the total weight of the composition, but is not limited thereto. For example, the taurine of the present invention may be contained in an amount of about 0.0001 to 5 wt%, about 0.0005 to 5 wt%, about 0.001 to 5 wt%, about 0.01 to 5 wt%, about 0.0001 to 3 wt%, about 0.0005 to 3 wt%, about 0.001 to 3 wt%, about 0.01 to 3 wt%, about 0.0001 to 1 wt%, about 0.0005 to 1 wt%, about 0.001 to 1 wt%, or about 0.01 to 1 wt% based on the total weight of the composition.

[0037] In the present invention, the term "about" may be presented before a specific numerical value. As used herein, the term "about" encompasses not only the exact number described after the term, but also a range that is or is nearly that number. Whether a number is or is nearly the specific number described can be determined based on the context in which it is presented. For example, the term "about" may refer to a range of -10% to +10% of a numerical value. For another example, the term "about" may refer to a range of -5% to +5% of a given numerical value. However, this is not a limitation.

[0038] The above composition may contain chlorogenic acid:taurine in a weight ratio of 1:80 to 120. Specifically, it may contain chlorogenic acid:taurine in a weight ratio of 1:120, 1:110, 1:100, 1:90, or 1:80, and more specifically, it may contain chlorogenic acid:taurine in a weight ratio of 1:100, but is not limited thereto. When chlorogenic acid and taurine are contained in the above weight ratio, the content of chlorogenic acid may be contained in a low content. For example, the composition may contain chlorogenic acid in an amount of 0.1 to 50 ppm, 0.1 to 40 ppm, 0.1 to 30 ppm, 0.1 to 20 ppm, 0.1 to 10 ppm, 0.5 to 50 ppm, 0.5 to 40 ppm, 0.5 to 30 ppm, 0.5 to 20 ppm, 0.5 to 10 ppm, 1 to 50 ppm, 1 to 40 ppm, 1 to 30 ppm, 1 to 20 ppm, 1 to 10 ppm, 5 to 50 ppm, 5 to 40 ppm, 5 to 30 ppm, 5 to 20 ppm, or 5 to 10 ppm, based on the total weight of the composition.

[0039]

[0040] According to one embodiment of the present invention, when 50 ppm of chlorogenic acid was applied to the product, significant discoloration occurred, making product application difficult, and cytotoxicity was confirmed. Furthermore, it was confirmed that when chlorogenic acid and taurine were combined, they were more effective in wound healing than when chlorogenic acid and taurine were applied alone.

[0041] In the present invention, the cosmetic composition may have effects such as skin wound healing, skin elasticity enhancement, skin wrinkle improvement, skin moisturizing, skin radiance improvement, or anti-inflammation, but is not limited thereto.

[0042] "Skin wound recovery" in the present invention refers to regenerating skin by increasing the expression levels of wound healing-related genes and cell proliferation-related genes present in damaged skin areas. The term "skin wound recovery" may be used interchangeably with terms such as "skin damage recovery" and "skin regeneration promotion."

[0043] According to a specific example, when the degree of wound healing was measured after treating keratinocytes with a composition containing chlorogenic acid and taurine of the present invention, it was confirmed that when chlorogenic acid and taurine were treated simultaneously, there was a synergistic effect on wound healing compared to when chlorogenic acid or taurine was treated alone.

[0044] "Increasing skin elasticity" in the present invention means alleviating the degree of sagging or stretching of the skin. This refers to the maintenance of skin elasticity when elastic fibers composed of elastin exist together with collagen fibers, and elastin and collagen are sufficiently present. In the present invention, "improving wrinkles" refers to suppressing or inhibiting the formation of wrinkles in the skin, or alleviating wrinkles that have already formed.

[0045] According to a specific example, after treating HaCaT cells with a composition containing chlorogenic acid and taurine of the present invention, the expression level of TIMP-2, which is effective in collagen synthesis and wrinkle improvement, was confirmed. As a result, it was confirmed that when chlorogenic acid and taurine were treated simultaneously, there was a synergistic effect in improving skin elasticity and wrinkles, compared to when chlorogenic acid or taurine was treated alone. In addition, it was confirmed that the expression of CLDN1 increased, confirming the synergistic effect in strengthening the skin barrier.

[0046] "Skin moisturizing" in the present invention refers to increasing skin moisture and maintaining it in a moist state. This moisturizing effect can help improve wrinkles and increase skin elasticity.

[0047] According to a specific example, after treating HaCaT cells with a composition containing chlorogenic acid and taurine of the present invention, the expression of HAS3 and AQP3 increased when chlorogenic acid and taurine were treated simultaneously, compared to when chlorogenic acid or taurine was treated alone, confirming a synergistic effect in improving skin moisturizing.

[0048] In the present invention, "improving skin radiance" encompasses making skin color more radiant and providing a glowing complexion. Factors that significantly affect skin radiance include acne (inflammation), elasticity, and pigmentation. Skin radiance can be influenced by a number of external and internal factors. External factors include exposure to sunlight, changes in temperature and humidity, and exposure to pollutants. Internal factors that affect skin radiance include stress, fatigue, hormonal changes, epithelial dehydration, impaired skin barrier function, and even aging. These external and internal factors tend to dull skin color, making it appear uneven, dull, pale, or even fragile, and can promote or even worsen skin imperfections. The cosmetic composition of the present invention may improve skin radiance.

[0049] According to a specific example, a composition containing chlorogenic acid and taurine of the present invention was applied to the face of a test subject, and it was confirmed that skin radiance was improved after 2 or 4 weeks of use compared to before use.

[0050] In the present invention, "anti-inflammation" refers to an action that suppresses inflammation. The regulation of the inflammatory response is known to be extremely complex, and is known to be aimed at enhancing the body's repair system and reducing damage. However, if the inflammatory response persists due to repeated tissue damage or regeneration, ROS and RNS are excessively produced in inflammation-related cells, resulting in permanent genetic alterations. Thus, ROS and RNS are deeply related to the inflammatory response that regulates the functions of various cells in the body. During the inflammatory process, large amounts of proinflammatory cytokines, nitric oxide (NO), and prostaglandin E2 (PGE2) are produced by inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Inflammation is a cause of various inflammatory diseases, and the composition including the mixture of chlorogenic acid and taurine of the present invention can have a preventive and improving effect on various inflammatory diseases through anti-inflammatory action.

[0051] According to a specific example, after treating HaCaT cells with a composition containing chlorogenic acid and taurine of the present invention, it was confirmed that the expression of IL6 and IL1α decreased when chlorogenic acid and taurine were treated simultaneously, compared to when chlorogenic acid or taurine was treated alone, thereby confirming the synergistic effect for anti-inflammation / sedation.

[0052] The cosmetic composition according to the present invention can be prepared in a formulation selected from the group consisting of a solution, an external ointment, a cream, a foam, a nourishing toner, an emollient toner, a pack, an emollient, a milky lotion, a makeup base, an essence, a soap, a liquid cleanser, a bath agent, a sunscreen cream, a sun oil, a suspension, an emulsion, a paste, a gel, a lotion, a powder, a soap, a surfactant-containing cleansing, an oil, a powder foundation, an emulsion foundation, a wax foundation, a patch, and a spray, but is not limited thereto.

[0053] In addition, the cosmetic composition of the present invention may additionally include one or more cosmetically acceptable carriers that are blended with general skin cosmetics, and may appropriately blend conventional ingredients such as oil, water, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, fragrances, etc., but is not limited thereto.

[0054] The cosmetically acceptable carrier included in the cosmetic composition of the present invention varies depending on the formulation.

[0055] When the formulation of the present invention is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or a mixture thereof may be used as a carrier component.

[0056] When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof may be used as a carrier component, and particularly in the case of a spray, a propellant such as chlorofluorohydrocarbon, propane / butane or dimethyl ether may be additionally included.

[0057] When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizer or an emulsifier is used as a carrier component, and for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil can be used, and in particular, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan can be used.

[0058] When the formulation of the present invention is a suspension, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth, etc. can be used as a carrier component.

[0059] When the formulation of the present invention is soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils, glycerol, sugars, etc. can be used as carrier components.

[0060] The cosmetic composition of the present invention may contain not only the chlorogenic acid and taurine, but also auxiliary agents commonly used in cosmetic compositions, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, fragrances, fillers, blocking agents, pigments, deodorants, and dyes.

[0061] As another aspect for achieving the above purpose, the present invention provides a functional food composition comprising chlorogenic acid and taurine as active ingredients.

[0062] In the present invention, the functional food composition may have effects such as skin wound healing, skin elasticity enhancement, skin wrinkle improvement, skin moisturizing, skin radiance improvement, or anti-inflammation, but is not limited thereto.

[0063] The above-described chlorogenic acid, taurine, skin wound healing, skin elasticity enhancement, wrinkle improvement, skin moisturizing, skin radiance improvement, and anti-inflammation properties are as described above. The above-described functional food composition may be used in the form of a health functional food, but is not limited thereto.

[0064] The functional food composition of the present invention, which includes chlorogenic acid and taurine as active ingredients, may include a food additive acceptable from a food science perspective in addition to the active ingredients.

[0065] In the present invention, "food supplement additive" means a component that can be added to food as an auxiliary, and can be appropriately selected and used by those skilled in the art as added in the manufacture of health functional foods of each formulation. Examples of food supplement additives include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc., but the types of food supplement additives of the present invention are not limited by the above examples.

[0066] The functional food composition of the present invention may include a health functional food. In the present invention, "health functional food" refers to a food manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. using raw materials or ingredients with useful functionality for the human body. Here, "functionality" means obtaining a beneficial effect for health purposes, such as regulating nutrients for the structure and function of the human body or physiological functions. The health functional food of the present invention can be manufactured by a method commonly used in the art, and during the manufacturing process, raw materials and ingredients commonly added in the art can be added. In addition, the formulation of the health functional food can be manufactured without limitation as long as it is a formulation recognized as a health functional food. The food composition of the present invention can be manufactured in various forms, and unlike general drugs, it has the advantage of not causing side effects that may occur with long-term use of drugs because it uses food as a raw material. In addition, the health functional food of the present invention is highly portable, and can be consumed as a supplement to promote skin wound healing, skin elasticity enhancement, wrinkle improvement, skin moisturizing, skin radiance improvement, or anti-inflammatory effects.

[0067] There is no limitation on the form that the health functional food of the present invention can take, and it can include all foods in the conventional sense, and can be used interchangeably with terms known in the art such as functional food. In addition, the health functional food of the present invention can be manufactured by mixing other appropriate auxiliary ingredients that can be included in foods and known additives according to the choice of a person skilled in the art. Examples of foods that can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and it can be manufactured by adding it to juice, tea, jelly, and juice manufactured using the compound represented by the chemical formula 1 according to the present invention as a main ingredient. It also includes foods used as feed for animals.

[0068] As another aspect for achieving the above purpose, the present invention provides a pharmaceutical composition comprising chlorogenic acid and taurine as active ingredients.

[0069] In the present invention, the above-mentioned pharmaceutical composition may have effects such as skin wound healing, skin elasticity enhancement, skin wrinkle improvement, skin moisturizing, skin radiance improvement, or anti-inflammation, but is not limited thereto.

[0070] The above chlorogenic acid, taurine, skin wound healing, skin elasticity enhancement, wrinkle improvement, skin moisturizing, skin radiance improvement, and anti-inflammation are as described above.

[0071] In addition to the above-mentioned ingredients, the quasi-drug composition of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent, as needed. The pharmaceutically acceptable carrier, excipient, or diluent is not limited as long as it does not impair the effects of the present invention, and may include, for example, fillers, bulking agents, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, fragrances, preservatives, etc.

[0072] Representative examples of pharmaceutically acceptable carriers, excipients or diluents of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, acacia gum, alginate, calcium phosphate, calcium carbonate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil, injectable esters, withepsol, macrogol, Tween 61, cacao butter, lauric acid, etc.

[0073] In addition, when the composition comprising chlorogenic acid and taurine of the present invention as active ingredients is used as a quasi-drug, it may additionally contain one or more active ingredients having the same or similar functions. For example, it may include known skin wound healing, elasticity enhancement, wrinkle improvement, moisturizing, or anti-inflammatory ingredients. If additional skin wound healing, elasticity enhancement, wrinkle improvement, moisturizing, and anti-inflammatory ingredients are included, the skin wound healing, elasticity enhancement, wrinkle improvement, moisturizing, and anti-inflammatory effects of the composition of the present invention may be further increased. When adding the above-mentioned ingredients, skin safety due to complex use, ease of formulation, and stability of the active ingredients may be taken into consideration. The above-mentioned quasi-drug composition may include whitening ingredients known in the art, such as substances that inhibit tyrosinase enzyme activity, such as kojic acid and arbutin, hydroquinone, vitamin C (L-ascorbic acid); The composition may further comprise one or more ingredients selected from the group consisting of skin elasticity, wrinkle improvement, or moisturizing ingredients known in the art, such as retinoic acid, TGF, animal placenta-derived proteins, betulinic acid, and chlorella extracts; and derivatives thereof and various plant extracts. The additional ingredients may be comprised in an amount of 0.0001 wt% to 10 wt% based on the total weight of the composition, and the content range may be adjusted according to requirements such as skin safety and ease of use.

[0074] The pharmaceutical composition of the present invention may include, but is not limited to, a disinfectant, a shower foam, an ointment, a wet tissue, a coating agent, etc., and the formulation method, dosage, method of use, components, etc. of the pharmaceutical composition may be appropriately selected from conventional techniques known in the art.

[0075] In addition, the pharmaceutical composition of the present invention comprising the chlorogenic acid and taurine as active ingredients can be used for skin wound healing, skin elasticity enhancement, skin wrinkle improvement, skin moisturization, skin radiance improvement, or anti-inflammation, including a step of applying the composition to the skin of a subject. The subject includes, without limitation, mammals including rats, livestock, and humans.

[0076]

[0077] As another aspect for achieving the above object, the present invention provides a method for improving skin, comprising a step of applying or administering to a subject a composition comprising chlorogenic acid and taurine as active ingredients.

[0078] The above skin improvement may include, but is not limited to, skin wound healing, skin elasticity enhancement, skin wrinkle improvement, skin moisturizing, skin radiance improvement, and / or anti-inflammation.

[0079] The above composition may be, but is not limited to, a cosmetic, functional food or quasi-drug composition.

[0080] In the present invention, the term "application" means any method of bringing the composition according to the present invention into contact with the skin of an individual by any suitable method, thereby aiming at allowing the composition to be absorbed into the skin.

[0081] When the composition of the present invention is applied to the skin of an individual, it may have the effects of skin wound recovery, skin elasticity enhancement, skin wrinkle improvement, skin moisturizing, skin radiance improvement, and / or inflammation improvement, and may include a step of applying or administering the composition to the individual in an amount effective to exhibit the above effects.

[0082] In the present invention, the term “administration” is a general term that refers to providing a given substance to an individual by any appropriate method, and the administration route may be through any general route as long as it can reach the target skin.

[0083]

[0084] As another aspect for achieving the above purpose, the present invention provides a composition comprising chlorogenic acid and taurine as effective ingredients for improving skin.

[0085] In addition, the present invention provides a use for producing a skin improvement composition comprising chlorogenic acid and taurine as effective ingredients.

[0086] In addition, the present invention provides a use of a composition comprising chlorogenic acid and taurine as active ingredients, characterized in that the composition is used for the purposes of skin wound recovery, skin elasticity enhancement, skin wrinkle improvement, skin moisturization, skin radiance improvement, and / or anti-inflammation.

[0087]

[0088] Hereinafter, the present invention will be described in more detail through examples. These examples are intended merely to illustrate the present invention and are not to be construed as limiting the scope of the present invention.

[0089]

[0090] Experimental Example 1: Appropriate content of chlorogenic acid and taurine

[0091] 1-1. Formulation discoloration analysis

[0092] As a result of applying 1 to 50 ppm of chlorogenic acid to the O / W emulsion composition, as shown in Fig. 1, it was confirmed that 50 ppm showed discoloration in one day, and 10 ppm of chlorogenic acid showed no discoloration, so it was determined that 10 ppm of chlorogenic acid was more applicable to the product.

[0093]

[0094] 1-2. Evaluation of cell proliferation capacity

[0095] Keratinocytes (HaCaT) were seeded in 24-well plates (5 X 10 4After culturing at 37°C for 24 hours (cells / well), the material was treated and cultured for another 24 hours, and then cell proliferation was evaluated using Cell Counting Kit-8 (CCK-8).

[0096] As a result, it was confirmed that cell proliferation was significantly reduced when treated with 50 ppm of chlorogenic acid, so 10 ppm of chlorogenic acid was applied.

[0097]

[0098] 1-3. Wound healing ability evaluation

[0099] 7 X 10 of keratinocytes (HaCaT) 5 After diluting to cells / mL, 70 μl was seeded into each well of an ibidi culture-insert 2-well plate, and material treatment (10 ppm chlorogenic acid: 500 ppm, 1000 ppm, 1500 ppm, 2000 ppm taurine treatment) was performed 24 hours later. After 16 hours of incubation at 37°C, images were taken under a microscope, and quantified using the ImageJ wound healing size tool.

[0100] As a result, as shown in Fig. 2, it was confirmed that when chlorogenic acid:taurine was treated at a ratio of 1:100, the wound healing ability was better than when treated at a ratio of 1:50, 1:150, and 1:200.

[0101]

[0102] Accordingly, in the following experiment, chlorogenic acid:taurine was tested at a ratio of 1:100.

[0103]

[0104] Experimental Example 2: Evaluation of the Synergistic Effect of Taurine and Chlorogenic Acid on Wound Healing Promotion

[0105] To evaluate the synergistic effect of taurine and chlorogenic acid in promoting wound healing in vitro, a wound healing assay was conducted. 1x10 4 Human keratinocytes (HaCaT, AddexBio; cat #T0020001) were seeded at 1 cell / well and cultured at 37°C, 5% CO2 for 24 hours. The silicone wall was removed, the sample was dissolved in 2 ml of medium, treated with the cells, and cultured for another 16 hours at 37°C, 5% CO2. The area covered by the proliferation of proliferated keratinocytes was photographed using a 100X microscope. The wound closure area was calculated using the ImageJ / Fiji® plugin Wound_healing_size_tool (AlejandraArnedo), and the degree of wound healing was compared with the control group. If the value of the covered area of ​​the experimental group was significantly higher than that of the control group, the wound healing effect was determined to be present.

[0106] As a result, when treated with 10 ppm of chlorogenic acid and 1000 ppm of taurine, the wound closure area increased by 33% (X) and 25% (Y), respectively. In addition, when chlorogenic acid and taurine at the corresponding concentrations were treated simultaneously, the wound closure area increased by 111% (T, effect measurement value). Since this is greater than 49%, which is the Colby equation prediction equation (E1) for the combination of the two substances, it was determined that there was a synergistic effect on wound healing (Fig. 3).

[0107]

[0108] Colby formula E1=X+Y-(XY / 100)

[0109]

[0110] Experimental Example 3: Evaluation of the Synergistic Anti-Wrinkle Effect of Taurine and Chlorogenic Acid

[0111] To evaluate the in vitro synergistic effect of taurine and chlorogenic acid on wrinkle improvement, a protein expression analysis was performed. 1x10 5 HaCaT cells were seeded at 10 cells / well and cultured at 37°C, 5% CO2 for 24 hours. The sample was dissolved in 1 mL of medium, treated with the cells, and cultured for another 24 hours at 37°C, 5% CO2. The cultured supernatant was stored at 20°C, then thawed and the TIMP-2 expression level was analyzed by ELISA (enzyme-linked immunosorbent assay). Human TIMP-2 DuoSet ELISA Kit (DY971, R&D systems, MN, USA) was used, and the experiment was conducted according to the manufacturer's manual. TIMP-2 is known to have an anti-wrinkle effect because it inhibits the expression and activity of matrix metalloproteinases (MMPs) involved in collagen degradation.

[0112] As a result, when treated with 5 ppm of chlorogenic acid, TIMP-2 expression increased by 6.1% (X), and when treated with 500 ppm of taurine, TIMP-2 expression decreased by 6.2% (Y=-6.2). In addition, when chlorogenic acid and taurine at the corresponding concentrations were treated simultaneously, TIMP-2 expression increased by 27.6% (T, effect measurement value). This is significantly greater than 0.4%, which is the Colby equation prediction formula (E1) for the combination of the two substances, so it can be judged that there is a synergistic effect for improving wrinkles.

[0113]

[0114] Experimental Example 4: Evaluation of the synergistic moisturizing effect of taurine and chlorogenic acid.

[0115] To evaluate the in vitro moisturizing synergy effect of taurine and chlorogenic acid, mRNA expression analysis was performed. 5x10 4HaCaT cells were seeded at 100 cells / well and cultured at 37°C, 5% CO2 for 24 hours. Samples were dissolved in 1 mL of medium and treated with cells, and cultured for another 24 hours at 37°C, 5% CO2. To extract RNA from the cultured cells, RNA prep was performed according to the manual of AccuPrep® Universal RNA Extraction Kit (BIONEER; cat #K-3140). cDNA was produced from the extracted RNA using AccuPower® RocketScript™ Cycle RT PreMix (dT20) (BIONEER; cat #K-2202). Real-time quantitative polymerase chain reaction was performed with the cDNA produced in this way. Taqman universal master mix II, with UNG (ABI; cat #4440045, USA) was used, and Taqman was used as a probe. TM Probes GAPDH (4333764F, reference gene), HAS3 (Hs00193436_m1), and AQP3 (HS01105469_G1) were used. PCR reactions were performed according to the ABI7500 Real Time PCR system protocol, and data were obtained using ABI software (delta delta Ct method).

[0116]

[0117] Delta Ct: Ct (target gene) - Ct (GAPDH)

[0118] Delta delta Ct: delta Ct (treatment group) - delta Ct (control group)

[0119]

[0120] The delta delta Ct value obtained by the above calculation formula can be viewed as the number of genes amplified in the sample treatment group compared to the control group, and since the gene is amplified by the power of 2, the expression amount was calculated as 2^(-delta delta Ct). If the expression amount of the sample treatment group is higher than that of the control group, it was determined that there is an effect of promoting the expression of the corresponding gene. It is known that when the expression of HAS3 (hyaluronic acid synthase 3) increases, it promotes hyaluronic acid synthesis and has a moisturizing effect. In addition, AQP3 (aquaporin 3) is a membrane transmembrane protein that regulates the movement of water, and it is generally accepted that when this expression increases, there is a moisturizing effect.

[0121] As a result of the analysis, HAS3 expression increased by 92% (X) and 94% (Y) when treated with 5 ppm of chlorogenic acid and 500 ppm of taurine, respectively. In addition, when chlorogenic acid and taurine at the corresponding concentrations were treated simultaneously, HAS3 expression increased by 1339% (T, effect measurement value), which is significantly greater than 100%, which is the Colby equation predicted by the combination of the two substances (E1). In addition, when chlorogenic acid at 10 ppm and taurine at 1000 ppm were treated simultaneously, AQP3 expression increased by 45% (X) and 62% (Y), respectively. In addition, when chlorogenic acid and taurine at the corresponding concentrations were treated simultaneously, HAS3 expression increased by 89% (T, effect measurement value), which is significantly greater than 79%, which is the Colby equation predicted by the combination of the two substances (E1). Through this, it was determined that chlorogenic acid and taurine have a synergistic effect in improving skin moisturization.

[0122]

[0123] Experimental Example 5: Evaluation of the anti-inflammatory / sedative synergy of taurine and chlorogenic acid.

[0124] To evaluate the in vitro anti-inflammatory / sedative synergy effect of taurine and chlorogenic acid, mRNA expression analysis was performed. 5x10 4HaCaT cells were seeded at 1 cell / well and cultured for 24 hours at 37°C, 5% CO2. To induce inflammation, C. acnesRibotype 5 (Strain HL043PA1) was cultured at 65°C for 1 hour, heat-sterilized, and then diluted (OD=0.1) in 1 ml cell medium. The sample was dissolved in the cell medium, treated with the cells, and cultured for another 24 hours at 37°C, 5% CO2. To extract RNA from the cultured cells, RNA prep was performed according to the manual of AccuPrep® Universal RNA Extraction Kit (BIONEER; cat #K-3140). cDNA was produced from the extracted RNA using AccuPower® RocketScript™ Cycle RT PreMix (dT20) (BIONEER; cat #K-2202). Real-time quantitative polymerase chain reaction was performed with the cDNA produced in this way. Taqman universal master mix II, with UNG (ABI; cat #4440045, USA) was used, and Taqman was used as a probe. TM Probes GAPDH (4333764F, reference gene), GAPDH (4333764F), IL1α (Hs00899844_m1), and IL6 (Hs00174131_m1) were used. PCR reactions were performed according to the ABI7500 Real Time PCR system protocol, and data were obtained using ABI software (delta delta Ct method).

[0125]

[0126] Delta Ct: Ct(target gene) - Ct(GAPDH)

[0127] Delta delta Ct: delta Ct (treatment group) - delta Ct (control group)

[0128]

[0129] The delta delta Ct value obtained by the above calculation formula can be viewed as the number of genes amplified in the sample treatment group compared to the control group. Since the gene is amplified by the power of 2, the expression amount was calculated as 2^(-delta delta Ct). If the expression amount in the sample treatment group is lower than that in the control group, it was determined that there was an effect of suppressing the expression of the corresponding gene. IL6 and IL1 are representative inflammatory cytokines, and it is generally accepted that suppressing these genes has a skin soothing effect.

[0130] As a result of the analysis, IL6 expression increased by 2% when treated with 10 ppm of chlorogenic acid (X=-2), and decreased by 52% (Y) when treated with 1000 ppm of taurine. In addition, when chlorogenic acid and taurine at the corresponding concentrations were treated simultaneously, IL6 expression decreased by 69% (T, effect measurement value), which is significantly greater than the 48% predicted by Colby's equation (E1) for the combination of the two substances. In addition, when chlorogenic acid at 10 ppm and taurine at 1000 ppm were treated, IL1α expression decreased by 2.1% (X) and 45.3% (Y), respectively. In addition, when chlorogenic acid and taurine at the corresponding concentrations were treated simultaneously, IL1α expression decreased by 47.4% (T, effect measurement value), which is greater than the 46.6% predicted by Colby's equation (E1) for the combination of the two substances. Through this, it can be said that chlorogenic acid and taurine have a synergistic effect on skin soothing.

[0131]

[0132] Experimental Example 6: Evaluation of the synergistic efficacy of taurine and chlorogenic acid in improving the barrier.

[0133] To evaluate the in vitro barrier improvement synergy effect of taurine + chlorogenic acid, protein expression analysis was performed using immunostaining.

[0134] Specifically, 5x10 in a 24-well plate 4HaCaT cells were seeded at 1 cell / well and cultured at 37°C, 5% CO2 for 24 hours. Samples were dissolved in the medium and treated with the cells, and cultured for another 24 hours at 37°C, 5% CO2. After washing with PBS, cells were fixed with 4% paraformaldehyde for 10 minutes at room temperature. Next, permeabilization was performed with 0.1% Triton X-100 in PBS, and blocked with PBS containing 5% FBS and 1% BSA. After treatment with the primary antibody against CLDN1 (200:1 dilution, Abcam, Cambridge, UK), a protein that constitutes the skin barrier, for 12 hours at 4°C, the cells were treated with the Alexa 594 nm conjugated secondary antibody (1000:1 dilution, Thermofisher scientific, MA, USA) for 1 hour at room temperature. Cell nuclei were stained with DAPI (2000:1 dilution, Thermofisher Scientific, MA, USA) for 10 minutes. Fluorescence imaging was performed using EVOS TM It was performed using the FL Auto2 Imaging System (Thermofisher scientific, MA, USA).

[0135] Quantitative results showed that CLDN1 (claudin-1) expression increased by 31.2% (X) and 43.3% (Y) when treated with 5 ppm of chlorogenic acid and 500 ppm of taurine, respectively. In addition, when chlorogenic acid and taurine at the corresponding concentrations were treated simultaneously, CLDN1 expression increased by 95.9% (T, effect measurement value), which is a greater value than the Colby equation prediction equation (E1) of 61.0% for the combination of the two substances.

[0136] When treated with 10 ppm of chlorogenic acid and 1000 ppm of taurine, CLDN1 expression increased by 44.9% (X) and 59.1% (Y), respectively. In addition, when chlorogenic acid and taurine at the corresponding concentrations were treated simultaneously, CLDN1 expression increased by 124.7% (T, effect measurement value), which is a significantly greater value than the Colby equation prediction equation (E1) of 77.5% for the combination of the two substances. Through this, it was determined that chlorogenic acid and taurine have a synergistic effect in strengthening the skin barrier (Fig. 4, Table 1).

[0137] Synergistic efficacy of taurine + chlorogenic acid for strengthening the barrier Concentration (ppm) Chlorogenic acid treatment alone (%) Taurine treatment alone (%) Simultaneous treatment Observed efficacy (%) Efficacy calculated by Colby formula (%) 5+500 31.24 3.39 5.96 1.010+1000 44.95 9.11 24.77 7.5

[0138]

[0139] Experimental Example 7: Evaluation of Taurine + Chlorogenic Acid for Improving Human Skin Glow

[0140] It is known that the factors that have the greatest influence on skin radiance include acne (inflammation), elasticity, and pigmentation (Goodman, GJ et al., (2024). Journal of Cosmetic Dermatology, 23(1), 161-171.). Therefore, the inventors of the present invention confirmed that the composition of the present invention containing taurine and chlorogenic acid has anti-inflammation and / or elasticity effects, and also attempted to determine whether it is effective in improving skin radiance.

[0141] Subjects were recruited from adult women aged 30 to 68 years. Evaluations were conducted using a gloss meter (Multi Gloss 268 PLUS, Konica Minolta, Japan) and a digital camera (EOS 750D, Canon, Japan). The same researcher measured the forehead area of ​​all subjects, and the 60° value was used for analysis. In addition, the left facial area of ​​all subjects was photographed with a digital camera under low illumination (color temperature adjustment: 3500K). A serum formulation containing 10 ppm of chlorogenic acid and 1000 ppm of taurine was used twice daily. An increase in the measured value compared to before use indicates improvement.

[0142] As a result, as shown in Fig. 5, there was a statistically significant (p<.001) increase in the test substance application area after 2 weeks of use and after 4 weeks of use compared to before use. This suggests that the test substance helps improve skin radiance (under low light conditions).

[0143]

[0144] From the above description, those skilled in the art will understand that the present invention can be implemented in other specific forms without altering its technical spirit or essential characteristics. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as encompassing all changes or modifications derived from the meaning and scope of the following claims and their equivalent concepts, rather than the detailed description above.

Claims

1. A cosmetic composition containing chlorogenic acid and taurine as active ingredients.

2. In paragraph 1, The above composition is a cosmetic composition for use in healing skin wounds, improving skin elasticity, improving skin wrinkles, moisturizing skin, improving skin radiance, or anti-inflammation.

3. In paragraph 1, A cosmetic composition comprising chlorogenic acid and taurine in a weight ratio of 1:80 to 120.

4. A functional food composition containing chlorogenic acid and taurine as active ingredients.

5. In paragraph 4, The above composition is a functional food composition for use in healing skin wounds, improving skin elasticity, improving skin wrinkles, moisturizing skin, improving skin radiance, or anti-inflammation.

6. A pharmaceutical composition containing chlorogenic acid and taurine as active ingredients.

7. In paragraph 6, The above composition is a pharmaceutical composition for use in healing skin wounds, improving skin elasticity, improving skin wrinkles, moisturizing skin, improving skin radiance, or anti-inflammation.

8. A method for improving skin, comprising a step of applying or administering to an object a composition containing chlorogenic acid and taurine as active ingredients.

9. Use of a composition containing chlorogenic acid and taurine as active ingredients for improving skin.

Images